Socio-demographic and other risk factors associated with HBV potential infectivity among Hepatitis B Surface Antigen Negative blood donors

  • Olusogo Ebenezer Busari Department of Haematology, Afe Babalola University, Ado Ekiti, Ekiti State, Nigeria.
  • Omotola Toyin Ojo Department of Haematology and Blood Transfusion, Olabisi Onabanjo University Teaching Hospital, Sagamu, Ogun State, Nigeria http://orcid.org/0000-0002-7211-650X
  • Yetunde Adebisi Aken'Ova Department of Haematology University College Hospital, Ibadan, Oyo State, Nigeria
Keywords: Anti-HBc, Blood donors, HBsAg, Hepatitis, Risk factors, Socio-demographics

Abstract

Background: There have been cases of post-transfusion hepatitis in spite of transfusion of hepatitis B surface antigen negative blood unit.

Objective: To determine the socio-demographic and risk factors associated with positivity of anti-HBc among Hepatitis B surface antigen negative blood donors.

Methods: A cross-sectional study was carried out among 490 HBsAg negative blood donors. The participants were tested for anti-HBc using ELISA kits. A structured questionnaire was used to obtain socio-demographic data and other possible risk factors.

Results: The mean age of the participants was 32.5 ± 9.5 years with male predominance of 462 (94.3%) while 375 (76.5%) were first time donors. Of the 490 HBsAg negative blood donors, 89 (18.2%) were positive for anti-HBc.

The highest prevalence of anti-HBc occurred in the 26-34 years age group. Independent risk factors associated with the presence of anti-HBc included age (p = 0.049), marital status (p = 0.003), dental and surgical procedure (p<0.001), traditional practices such as tattoo, body piercing and scarification (p<0.001) and previous blood transfusion (p = 0.016).

Conclusion: Age, marital status, traditional and cultural practices like scarifications, tattoo and body piercing and history of blood transfusion were risk factors associated with HBV infection despite HBsAg negativity.

References

1. Salawu L, Adegoke AO, Aboderin AO, Huraina HA. Hepatitis B viral markers in surface antigen negative blood donors: The need to look beyond antibody Negativity. West Afr J Med 2011; 30(4): 292-295.
2. Behzad-Behbahani A, Mafi-Jenad A, Tabei SZ, Lankarani KB, Torab A, Moaddem A. Anti-HBc and HBV DNA detection in blood donors negative for hepatitis B virus surface antigen in reducing the risk of transfusion associated HBV infection. Indian J Med Res 2006; 123: 37-42.
3. Kaneko S, Feinstone SM, Miller RH. Rapid and sensitive method for the detection of serum hepatitis B virus DNA using the polymerase chain reaction technique. J Clin Microbiol 1989; 27(9): 1930-1933.
4. Schuurs AHWM, Kacaki J. Reversed haemagglutination test for the detection of hepatitis B antigen. Vox Sang Basel 1974; 27: 97-114.
5. Norder H, Courouce AM, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 1994; 198: 489–503.
6. Kao JH. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002; 17: 643-650.
7. Ola SO, Otegbayo JA, Odaibo GN, Olaleye OD, Olubuyide OI. Serum hepatitis C and hepatitis B surface antigenaemia in Nigerian patients with acute icteric hepatitis. West Afr J Med 2002; 21: 215-217.
8. Ajayi AO, Komolafe AO Ajumobi K. Seroprevalence of hepatitis B surface antigenaemia among health care workers in a Nigerian tertiary health institution. Niger J Clin Pract 2007; 10: 287-289.
9. Badru S, Akgun A. Diagnosis of hepatitis B infection and monitoring of treatment. J Clin Virol 2001; 21: 229-237.
10. Zervou EK, Dalekos GN, Boumba DS, Tsianos EV. Value of anti-HBc screening of blood donor for prevention of HBV infection: results of 3-year prospective study in Northwestern Greece. Transfusion 2001; 41: 652-658.
11. Kaviani MJ, Behbahani B, Mosallaii MJ, Sari-Aslani F, Taghavi SA. Occult hepatitis B virus infection and cryptogenic chronic hepatitis in an area with intermediate prevalence of HBV infection. World J Gastroenterol 2006; 12: 5048-5050.
12. Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004; 38: 158-168.
13. Ching-Lung L, Daniel S, Anna SL, Ting-Tsung C, Hugo C, Zachary G, et al. Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B. N Engl J Med 2006; 354: 1011-1020.
14. Ekwere TA, Ino-Ekanem M, Motilewa OO, Iquo AI.Pattern of blood donor deferral in a tertiary hospital, South-South, Nigeria: A three-year study review. Int J Blood Transfus Immunohematol 2014; 4: 7-12.
15. Damulak DO,Ogbenna AA, Adediran AO, Samuel E, Rufai O, Bolorunduro SA, et al. The pattern of blood donation in the National Blood Transfusion Service in North- Central Nigeria. Highland Med Res J 2014; 14(2): 80-84.
16. Jafarzadeh A, Arababadi MK, Mirzaee M, Pourazar A. Occult hepatitis B virus infection among blood donors with antibodies to hepatitis B core antigen. Acta Medica Iranica 2008; 46: 27-32.
17. Comanor L, Holland P. hepatitis B virus blood screening: unfinished agendas. Vox Sanguinis 2006; 91: 1-12.
18. Ola SO, Otegbayo JA, Odaibo GN, Olaleye OD, Olubuyide OI, Summerton CB, et al. Occult HBV infection among cohort of Nigeria. J Infect Dev Ctries 2009; 3(6): 442-446.
19. Ashim M, Ali R, Khan LA, Hussain SA, Singla R, Kar P. Significance of anti-HBc screening of blood donors and its association with occult hepatitis B virus infection: Implications for blood transfusion. Indian J Med 2010; 132: 312-317.
20. Chu CJ, Lok AS. Clinical utility of quantifying serum HBV DNA levels using PCR assays. J Hepatol 2002; 36: 549-551.
21. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen D, Colombo M, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008; 49: 652-657.
22. Schuurs AH, Kacaki J. Reversed haemagglutination test for the detection of hepatitis B antigen. Vox Sang Basel 1974; 27: 97-114.
23. Abraham. Evaluation of a new recombinant DNA hepatitis B vaccines. Vaccine 1999; 17: 1125-1129.
24. Salama II, Sami SM, Said ZNA, El-Sayed MH, El-Etreby LA, Rabah TM, et al. Effectiveness of hepatitis B virus vaccination program in Egypt: Multicenter national project. World J Hepatol 2015; 7(22): 2418–2426.
25. Damme PV. Long-term Protection After Hepatitis B Vaccine. J Infect Dis 2016; 214(1): 1–3.
26. Liang S, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Epidemiological serosurvey of hepatitis B in China–declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009; 27: 6550–6557.
27. Dettori S, Candido A, Kondili LA, Chionne P, Taffon S, Genovese D, et al. Identification of low HBV-DNA levels by nucleic acid amplification test (NAT) in blood donors. J Inf 2009; 59(2): 128-133.
28. Matos MA, Reis NR, Kozlowski AG, Teles SA, Motta-Castro AR, Mello FC, et al. Epidemiological study of hepatitis A, B and C in the largest Afro-Brazilian isolated community. Trans R Soc Trop Med and Hyg 2009; 103(9): 899-905.
29. El-Beltagy KE, Al Balawi IA, Almuneet M, Memish ZA. Prevalence of hepatitis B virus markers among blood donors in a tertiary hospital in Tabuk, northwestern Saudi Arabia. Int J Inf 2008; 12: 495-499.
30. El-Ghitany EM, Farghaly AG. Serological pattern of hepatitis B virus among HBsAg negative blood donors in Alexandria, Egypt. East Meditt Health J 2013; 19(7): 600-607.
Published
2018-06-17
Section
Original Research